Acidi grassi nella prevenzione e nella terapia in pediatria.

Translated title of the contribution: Fatty acids in prevention and therapy in pediatrics

C. Agostoni, E. Riva, G. Biasucci

Research output: Contribution to journalArticle

Abstract

Fatty acids (FA) are involved in both physiologic and pathologic biochemical pathways. Saturated FA (mainly 12-C and 14-C) are implicated in the development of hypercholesterolemia and early atherogenesis. On the contrary, monounsaturated and polyunsaturated FA (mainly 18:2 n-6 and n-3 very long-chain FA) have been claimed to have hypocholesterolemic and protective effects. In particular, oleic acid (18:1 n-9) seems to lower only the atherogenic fraction of circulating cholesterol (the low-density lipoproteins), leaving immodified the level of the protective fraction (the high-density lipoproteins). Polyunsaturated very long-chain FA have been recently studied for the prevention and therapy of atopic and cutaneous disorders, with conflicting results. In this respect, the 20:4 n-6 acts as proinflammatory agent, while the n-3 very long-chain FA could act as modulators of the immuno-allergic and inflammatory reactions. However, attention must be paid to the high peroxidative potential of the more unsaturated FA. Very recently, VLCFA have been considered for the therapy of some inherited disorders of metabolism. Monounsaturated very long-chain FA have been used in the treatment of x-linked adrenoleukodystrophy. A dietetic deficiency of polyunsaturated very long-chain FA has been observed in treated phenylketonuric children. Some inborn errors of metabolism could represent an useful model for better understanding the biochemistry of FA.

Original languageItalian
Pages (from-to)489-494
Number of pages6
JournalPediatria Medica e Chirurgica
Volume14
Issue number5
Publication statusPublished - Sep 1992

Fingerprint

Fatty Acids
Pediatrics
Therapeutics
Unsaturated Fatty Acids
Adrenoleukodystrophy
Inborn Errors Metabolism
Monounsaturated Fatty Acids
Dietetics
HDL Lipoproteins
Oleic Acid
Hypercholesterolemia
Biochemistry
LDL Cholesterol
Atherosclerosis
Hypersensitivity
Skin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Acidi grassi nella prevenzione e nella terapia in pediatria. / Agostoni, C.; Riva, E.; Biasucci, G.

In: Pediatria Medica e Chirurgica, Vol. 14, No. 5, 09.1992, p. 489-494.

Research output: Contribution to journalArticle

Agostoni, C. ; Riva, E. ; Biasucci, G. / Acidi grassi nella prevenzione e nella terapia in pediatria. In: Pediatria Medica e Chirurgica. 1992 ; Vol. 14, No. 5. pp. 489-494.
@article{9118312a98d645cea7cf3e25e3f439a0,
title = "Acidi grassi nella prevenzione e nella terapia in pediatria.",
abstract = "Fatty acids (FA) are involved in both physiologic and pathologic biochemical pathways. Saturated FA (mainly 12-C and 14-C) are implicated in the development of hypercholesterolemia and early atherogenesis. On the contrary, monounsaturated and polyunsaturated FA (mainly 18:2 n-6 and n-3 very long-chain FA) have been claimed to have hypocholesterolemic and protective effects. In particular, oleic acid (18:1 n-9) seems to lower only the atherogenic fraction of circulating cholesterol (the low-density lipoproteins), leaving immodified the level of the protective fraction (the high-density lipoproteins). Polyunsaturated very long-chain FA have been recently studied for the prevention and therapy of atopic and cutaneous disorders, with conflicting results. In this respect, the 20:4 n-6 acts as proinflammatory agent, while the n-3 very long-chain FA could act as modulators of the immuno-allergic and inflammatory reactions. However, attention must be paid to the high peroxidative potential of the more unsaturated FA. Very recently, VLCFA have been considered for the therapy of some inherited disorders of metabolism. Monounsaturated very long-chain FA have been used in the treatment of x-linked adrenoleukodystrophy. A dietetic deficiency of polyunsaturated very long-chain FA has been observed in treated phenylketonuric children. Some inborn errors of metabolism could represent an useful model for better understanding the biochemistry of FA.",
author = "C. Agostoni and E. Riva and G. Biasucci",
year = "1992",
month = "9",
language = "Italian",
volume = "14",
pages = "489--494",
journal = "Pediatria Medica e Chirurgica",
issn = "0391-5387",
publisher = "Vicenza Pediatria Medica E Chirurgica",
number = "5",

}

TY - JOUR

T1 - Acidi grassi nella prevenzione e nella terapia in pediatria.

AU - Agostoni, C.

AU - Riva, E.

AU - Biasucci, G.

PY - 1992/9

Y1 - 1992/9

N2 - Fatty acids (FA) are involved in both physiologic and pathologic biochemical pathways. Saturated FA (mainly 12-C and 14-C) are implicated in the development of hypercholesterolemia and early atherogenesis. On the contrary, monounsaturated and polyunsaturated FA (mainly 18:2 n-6 and n-3 very long-chain FA) have been claimed to have hypocholesterolemic and protective effects. In particular, oleic acid (18:1 n-9) seems to lower only the atherogenic fraction of circulating cholesterol (the low-density lipoproteins), leaving immodified the level of the protective fraction (the high-density lipoproteins). Polyunsaturated very long-chain FA have been recently studied for the prevention and therapy of atopic and cutaneous disorders, with conflicting results. In this respect, the 20:4 n-6 acts as proinflammatory agent, while the n-3 very long-chain FA could act as modulators of the immuno-allergic and inflammatory reactions. However, attention must be paid to the high peroxidative potential of the more unsaturated FA. Very recently, VLCFA have been considered for the therapy of some inherited disorders of metabolism. Monounsaturated very long-chain FA have been used in the treatment of x-linked adrenoleukodystrophy. A dietetic deficiency of polyunsaturated very long-chain FA has been observed in treated phenylketonuric children. Some inborn errors of metabolism could represent an useful model for better understanding the biochemistry of FA.

AB - Fatty acids (FA) are involved in both physiologic and pathologic biochemical pathways. Saturated FA (mainly 12-C and 14-C) are implicated in the development of hypercholesterolemia and early atherogenesis. On the contrary, monounsaturated and polyunsaturated FA (mainly 18:2 n-6 and n-3 very long-chain FA) have been claimed to have hypocholesterolemic and protective effects. In particular, oleic acid (18:1 n-9) seems to lower only the atherogenic fraction of circulating cholesterol (the low-density lipoproteins), leaving immodified the level of the protective fraction (the high-density lipoproteins). Polyunsaturated very long-chain FA have been recently studied for the prevention and therapy of atopic and cutaneous disorders, with conflicting results. In this respect, the 20:4 n-6 acts as proinflammatory agent, while the n-3 very long-chain FA could act as modulators of the immuno-allergic and inflammatory reactions. However, attention must be paid to the high peroxidative potential of the more unsaturated FA. Very recently, VLCFA have been considered for the therapy of some inherited disorders of metabolism. Monounsaturated very long-chain FA have been used in the treatment of x-linked adrenoleukodystrophy. A dietetic deficiency of polyunsaturated very long-chain FA has been observed in treated phenylketonuric children. Some inborn errors of metabolism could represent an useful model for better understanding the biochemistry of FA.

UR - http://www.scopus.com/inward/record.url?scp=0026919601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026919601&partnerID=8YFLogxK

M3 - Articolo

C2 - 1488303

AN - SCOPUS:0026919601

VL - 14

SP - 489

EP - 494

JO - Pediatria Medica e Chirurgica

JF - Pediatria Medica e Chirurgica

SN - 0391-5387

IS - 5

ER -